Addex Therapeutics Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Addex Therapeutics Ltd - Product Pipeline Review - 2016', provides an overview of the Addex Therapeutics Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Addex Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Addex Therapeutics Ltd - The report provides overview of Addex Therapeutics Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Addex Therapeutics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Addex Therapeutics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Addex Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Addex Therapeutics Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Addex Therapeutics Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Addex Therapeutics Ltd Snapshot 6 Addex Therapeutics Ltd Overview 6 Key Information 6 Key Facts 6 Addex Therapeutics Ltd - Research and Development Overview 7 Key Therapeutic Areas 7 Addex Therapeutics Ltd - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Addex Therapeutics Ltd - Pipeline Products Glance 15 Addex Therapeutics Ltd - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Addex Therapeutics Ltd - Early Stage Pipeline Products 17 IND/CTA Filed Products/Combination Treatment Modalities 17 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Addex Therapeutics Ltd - Drug Profiles 20 dipraglurant IR 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 dipraglurant ER 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ADX-71441 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ADX-71743 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ADX-88178 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ADX-92639 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ADX-90125 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ADX-95477 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Antagonize FSH Receptor for Women's Health 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules to Agonize TRKB for Alzheimer's Disease 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Modulate mGlu3 Receptor for CNS Disorders 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Addex Therapeutics Ltd - Pipeline Analysis 39 Addex Therapeutics Ltd - Pipeline Products by Target 39 Addex Therapeutics Ltd - Pipeline Products by Route of Administration 41 Addex Therapeutics Ltd - Pipeline Products by Molecule Type 42 Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action 43 Addex Therapeutics Ltd - Recent Pipeline Updates 44 Addex Therapeutics Ltd - Dormant Projects 51 Addex Therapeutics Ltd - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 ADX-10059 52 ADX-10061 52 ADX-71943 52 Addex Therapeutics Ltd - Company Statement 53 Addex Therapeutics Ltd - Locations And Subsidiaries 55 Head Office 55 Other Locations & Subsidiaries 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Addex Therapeutics Ltd, Key Information 6 Addex Therapeutics Ltd, Key Facts 6 Addex Therapeutics Ltd - Pipeline by Indication, 2016 8 Addex Therapeutics Ltd - Pipeline by Stage of Development, 2016 11 Addex Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 12 Addex Therapeutics Ltd - Out-Licensed Products in Pipeline, 2016 13 Addex Therapeutics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Addex Therapeutics Ltd - Phase II, 2016 15 Addex Therapeutics Ltd - Phase I, 2016 16 Addex Therapeutics Ltd - IND/CTA Filed, 2016 17 Addex Therapeutics Ltd - Preclinical, 2016 18 Addex Therapeutics Ltd - Discovery, 2016 19 Addex Therapeutics Ltd - Pipeline by Target, 2016 40 Addex Therapeutics Ltd - Pipeline by Route of Administration, 2016 41 Addex Therapeutics Ltd - Pipeline by Molecule Type, 2016 42 Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2016 43 Addex Therapeutics Ltd - Recent Pipeline Updates, 2016 44 Addex Therapeutics Ltd - Dormant Developmental Projects,2016 51 Addex Therapeutics Ltd - Discontinued Pipeline Products, 2016 52 Addex Therapeutics Ltd, Subsidiaries 55
List of Figures
Addex Therapeutics Ltd - Pipeline by Top 10 Indication, 2016 8 Addex Therapeutics Ltd - Pipeline by Stage of Development, 2016 11 Addex Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 12 Addex Therapeutics Ltd - Out-Licensed Products in Pipeline, 2016 13 Addex Therapeutics Ltd - Pipeline by Top 10 Target, 2016 39 Addex Therapeutics Ltd - Pipeline by Route of Administration, 2016 41 Addex Therapeutics Ltd - Pipeline by Molecule Type, 2016 42 Addex Therapeutics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 43
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.Read More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.